The role of purine analogue combinations in the management of acute leukemias

Hematological Oncology

Volumn 19, Issue 4, 2001, Pages 151-157

  Frewin, R J ^a   Johnson, S A ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Acute leukemias; Cytarabine; Cytosine arabinoside; Fludarabine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARABINOSIDE; CLADRIBINE; CYTARABINE; CYTOSINE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IDARUBICIN; MITOXANTRONE; PURINE DERIVATIVE; RETINOIC ACID;

ACUTE LEUKEMIA; BIOCHEMISTRY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVATION; HUMAN; INFECTION; LEUKEMIA CELL; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG SYNERGISM; HUMANS; LEUKEMIA; PURINES;

EID: 0035689357     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.686     Document Type: Review

References (37)

1. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity
2. Complete haematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia
3. Improved prospects for long-term survival in adults with acute myelogenous leukemia
4. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside
5. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
6. Saturation of 1-α-D-arabinosylcytosine 5′-triphosphate in leukemia cells during high-dose 1-α-D-arabinosylcytosine therapy
7. Modulation of arabinosyl metabolism by arabinosylnucleotides in human leukemia cells
8. Biochemical modulation of arabinosylcytosine for therapy of leukemias
9. 9-α-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma
10. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
11. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia
12. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia
13. Infections in patients with chronic lymphocytic leukemia treated with fliudarabine
14. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia
15. Treatment with G-CSF, fludarabine and Ara-C (FLAG) of poor prognosis AML and MDS: Biological effects and response
16. Effect of G-CSF on Ara-C induced programmed cell death in Human myeloid leukemic cells
17. Fludarabine + Ara-C + G-CSF: Cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells
18. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor
19. FLAG (Fludarabine + High-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'Poor Risk' acute myeloid leukemias
20. FLAG is a useful regimen for poor prognosis adult myeloid leukemias and myelodysplastic syndromes
21. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia
22. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
23. A multicenter, open, non-comparative Phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte-colony stimulating factor (FLAG) in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation
24. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia
25. FLAG (Fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children
26. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance
27. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia
28. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) in the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia
29. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor prognosis AML of childhood prior to allogenic or autologous bone marrow transplantation: Experiences of a phase II trial
30. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filigrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
31. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia
32. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
33. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions
34. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
35. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia
36. Engraftment of allogenic haematopoietic progenitor cells with purine analogue-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
37. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease